CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

300 mg EIDD-2801Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (7)

Name (Synonyms) Correlation
drug1824 Placebo (PBO) Wiki 1.00
drug239 Atorvastatin 40mg Wiki 1.00
drug2106 Rivaroxaban 2.5 MG Wiki 1.00
drug1679 Omeprazole 20mg Wiki 1.00
drug589 Clopidogrel 75mg Wiki 1.00
drug219 Aspirin 75mg Wiki 1.00
drug24 200 mg EIDD-2801 Wiki 0.71

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D054058 Acute Coronary Syndrome NIH 0.58

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 The Safety of EIDD-2801 and Its Effect on Viral Shedding of SARS-CoV-2

Designed as a single center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of EIDD-2801 on SARS-CoV-2 Virus Shedding in Newly Hospitalized Adults with polymerase chain reaction (PCR)-Confirmed COVID-19.

NCT04405739 SARS-CoV 2 Drug: 200 mg EIDD-2801 Drug: 300 mg EIDD-2801 Drug: Placebo (PBO)

Primary Outcomes

Description: Achievement of undetectable SARS-CoV-2 RNA by Day 5 in nasopharyngeal (NP) swabs by quantitative reverse transcription polymerase chain reaction (qPCR) after administration with EIDD-2801

Measure: Number of Participants that achieve Virologic Clearance after oral administration of EIDD-2801

Time: 28 days

Description: Incidence of Serious Adverse Events in subjects receiving EIDD-2801

Measure: Number of Participants With any Serious Adverse Events(SAEs) as assessed by DAIDS

Time: 28 days

Description: Incidence of Adverse Events in subjects receiving EIDD-2801

Measure: Number of Participants With any Adverse Events(AEs) as assessed by DAIDS

Time: 28 days

No related HPO nodes (Using clinical trials)